Clinical Trials
17 trialsNCT02954874 2026-05-15
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04052555 2026-05-13
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05491226 2026-04-20
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07015853 2026-04-20
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
NCT07217990 2026-02-17
NoCUT-BC
Ohio State University Comprehensive Cancer Center
Phase 1/2 Not yet recruiting
NCT03542175 2025-12-08
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03109080 2025-11-24
RadioPARP
Institut Curie
Phase 1 Completed
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT04837209 2025-10-01
NADiR
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03945721 2025-09-29
UNITY
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT07104266 2025-08-05
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Phase 2 Recruiting
NCT05233696 2022-12-06
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
University of Colorado, Denver
Phase 2 Withdrawn
NCT03872505 2021-08-25
PANDoRA
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT04481763 2020-07-22
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Jiangxi Provincial Cancer Hospital
Phase 1/2 Recruiting
NCT01375023 2015-06-22
Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer
European Institute of Oncology
Phase 2 Terminated
NCT02464774 2015-06-08
Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer
Sun Yat-sen University
Phase NA Unknown